Biotech
Jazz Just Paid $820 Million for an Epilepsy Drug Still Stuck in Phase 1 — and It's Meant for 2,500 People
Jazz Pharmaceuticals is paying $820M upfront — up to $1.32B — for Actio Biosciences and its Phase 1 KCNT1 epilepsy drug, aimed at just ~2,500 U.S. patients.